HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.31
-0.00 (-1.27%)
At close: 4:00PM EST

0.31 0.00 (0.00%)
After hours: 5:55PM EST

Stock chart is not supported by your current browser
Previous Close0.31
Open0.31
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.31 - 0.32
52 Week Range0.30 - 0.93
Volume567,470
Avg. Volume413,335
Market Cap9.879M
Beta-0.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
    Capital Cube14 days ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)

  • HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?
    Zacks Small Cap Researchlast month

    HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?

    Currently, commercialization efforts for both drugs have been hampered for different reasons.  The company faced some manufacturing hurdles related to Alferon.  However, the company has already taken steps towards increasing efficiency for production of Alferon.  The FDA rejected the NDA for Ampligen.  However, the company is working towards addressing the concerns raised by the FDA.  The company is also open to collaborative opportunities including out-licensing, co-research, co-development, co-promotion as well as co-marketing their product candidates.  Overall, we do see some significant headwinds for Hemispherix in the near term, however we believe there is a large market potential for the drugs and see significant value if they are able to overcome current roadblocks.

  • How Financially Strong Is Hemispherx Biopharma Inc (HEB)?
    Simply Wall St.last month

    How Financially Strong Is Hemispherx Biopharma Inc (HEB)?

    Investors are always looking for growth in small-cap stocks like Hemispherx Biopharma Inc (AMEX:HEB), with a market cap of USD $9.41M. However, an important fact which most ignore is: howRead More...

  • Capital Cube2 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Is Hemispherx Biopharma Inc (HEB) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.2 months ago

    Is Hemispherx Biopharma Inc (HEB) Thriving Or Barely Surviving In The Healthcare Sector?

    Hemispherx Biopharma Inc (AMEX:HEB), a USD$10.43M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • What’s The Outlook For Loss-Making Hemispherx Biopharma Inc (HEB)?
    Simply Wall St.2 months ago

    What’s The Outlook For Loss-Making Hemispherx Biopharma Inc (HEB)?

    As the USD $9.07M market cap Hemispherx Biopharma Inc (AMEX:HEB) released another year of negative earnings, investors may be on edge waiting for breakeven. The single most important question toRead More...

  • Capital Cube3 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : September 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of HEB earnings conference call or presentation 15-Aug-17 5:00pm GMT

    Q2 2017 Hemispherx Biopharma Inc Earnings Call

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube4 months ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : June 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube6 months ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : May 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of HEB earnings conference call or presentation 7-Apr-17 3:00pm GMT

    Q4 2016 Hemispherx Biopharma Inc Earnings Call

  • Capital Cube8 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : April 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
    Capital Cube8 months ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.02 million, Net Earnings of USD -1.17 million. Gross margins narrowed from -1,255.56% to -2650% compared to the same period last year, operating (EBITDA) margins now -23,506.25% from -9,192.59%. Change in operating ... Read more (Read more...)

  • Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks
    Insider Monkey10 months ago

    Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks

    By Khojinur Usmonov From low costs to expedited drug approval, President Trump recently met with big pharma CEOs about overhauling the entire system. Here’s what you need to know. A few weeks ago, President Donald Trump met with a series of biotech CEOs to discuss a historically major pain point for the industry: cutting the […]

  • Capital Cube11 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : January 3, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)